Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD and MAD Study of AJA001 in Healthy Volunteers
NCT06019065Phase 1Completed
- Sponsor
- AJNA BioSciences
- Start
- Sep 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AJA001 in Autism Spectrum Disorder (ASD) (4 arms), sponsored by AJNA BioSciences. Primary endpoints: Adverse Events up to 21 days, Serious Adverse Events up to 21 days and 8 more. Started Sep 2023; status: completed.
02
Drugs
AJA001
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT06019065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06019065.